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Background: Mediating DNA damage-induced apoptosis is an important genome-maintenance function of the
mismatch repair (MMR) system. Defects in MMR not only cause carcinogenesis, but also render cancer cells highly
resistant to chemotherapeutics, including alkylating agents. To understand the mechanisms of MMR-mediated
apoptosis and MMR-deficiency-caused drug resistance, we analyze a model alkylating agent (N-methyl-N’-nitro-N-
nitrosoguanidine, MNNG)-induced changes in protein phosphorylation and abundance in two cell lines, the
MMR-proficient TK6 and its derivative MMR-deficient MT1.
Results: Under an experimental condition that MNNG-induced apoptosis was only observed in MutSα-proficient
(TK6), but not in MutSα-deficient (MT1) cells, quantitative analysis of the proteomic data revealed differential
expression and phosphorylation of numerous individual proteins and clusters of protein kinase substrates, as well
differential activation of response pathways/networks in MNNG-treated TK6 and MT1 cells. Many alterations in
TK6 cells are in favor of turning on the apoptotic machinery, while many of those in MT1 cells are to promote
cell proliferation and anti-apoptosis.
Conclusions: Our work provides novel molecular insights into the mechanism of MMR-mediated DNA
damage-induced apoptosis.
Keywords: MNNG, DNA damage response, MSH6, SILAC-based quantitative mass spectrometryBackground
DNA mismatch repair (MMR) ensures genetic stability by
correcting biosynthetic errors, suppressing non-homologous
recombination, and mediating DNA damage-induced apop-
tosis [1-5]. While the first two functions of the MMR system
prevent mismatch-derived mutations, the apoptotic func-
tion of the system is to initiate programmed cell death in
cells with mutagenic and carcinogenic DNA lesions. The
latter function has been recognized as an important factor
in cancer chemotherapy, because tumor cells defective
in MMR are highly resistant to chemotherapeutic drugs,
including alkylating agents [6].
A key player in mammalian MMR is the major mis-
match recognition protein MutSα, which is composed of
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reproduction in any medium, provided the orother essential MMR factors that include MutLα, prolif-
erating cell nuclear antigen (PCNA), replication protein
A (RPA), exonuclease I, and DNA polymerases, MutSα tar-
gets the newly synthesized DNA strand for mismatch re-
moval [2,7]. Previous studies have revealed that besides
mismatch recognition, MutSα also recognizes base pairs
that contain a variety of modified or damaged bases, in-
cluding alkylating adduct O6-methylguanine (O6-MeG)
[6,8,9]. It has been suggested that recognition of the O6-
MeG:T or O6-MeG:C pair by MutSα possibly in complex
with MutLα, activates the ATR/ATM signaling network
to induce apoptosis, via either the futile cycle mechanism or
the direct interaction and signaling mechanism [1,2,6,8,10].
Many downstream targets, such as p53, Chk1, Chk2,
CDC25A, and SMC1, have been shown to play important
roles in the MMR-dependent alkylation-induced apoptosis
[8,10-12]. However, the molecular basis of the process,
particularly how the DNA damage signal in the nucleus
is transmitted to the cytoplasm/mitochondria to initiate
apoptosis is unknown.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteomics approaches, we have investigated in this
study a pair of MMR-proficient and -deficient human
lymphoblastoid cell lines, TK6 and MT1, for their
responses to the treatment of N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG), a widely used model chemical
for alkylating agent-induced mutagenesis, carcinogenesis,
and cell killing [13,14]. TK6 and MT1 are two closely-
related cell lines with dramatically different susceptibility
to MNNG-induced DNA damage. Both cells do not ex-
press methylguanine methyl transferase (MGMT), a direct
reversal repair enzyme that protects cells from MMNG-
induced cytotoxicity by transferring the methyl group
from O6-MeG to an internal cysteine of the enzyme,
restoring Watson-Crick base pairing at the site of the
damage [15]. MT1 cells were derived from MMR-proficient
TK6 cells by mutagenesis [16], and are defective in the
MSH6 subunit of MutSα, thereby defective in MMR
[17,18]. As a result, MT1 cells are 500-times more
resistant to killing by MNNG cytotoxicity than their
parental TK6 cells. The differential response of TK6 and
MT1 cells to MNNG underscores the critical role played
by MMR in alkylating agent-induced apoptosis/DNA
damage response (DDR) and makes these cells the ideal
subject for this study.
We demonstrate here that TK6 and MT1 cells display
significant differences in protein phosphorylation species,
stoichiometry and abundance, and in activation of protein
kinases and signaling networks in response to MNNG
treatment. Generally, MNNG-induced alterations in TK6
cells promote apoptosis, but changes in MT1 cells
stimulate cell proliferation. Our data provide significant
new insights into the mechanism of MMR-mediated
DNA damage-induced apoptosis.
Results and discussion
Cell cycle progression in MNNG-treated TK6 and MT1 cells
The goal of this study was to analyze MNNG-induced
changes in the proteome and phosphoproteome of the
MMR-proficient TK6 cell line and its MSH6-deficient
derivative, MT1 [17,18]. To confirm their susceptibility
to alkylating agent-induced apoptosis, TK6 and MT1 cells
were exposed to 0.5 μMMNNG and cell cycle progression
was analyzed by flow cytometry [19]. The results showed
a higher fraction of TK6 cells in S phase 24 h after MNNG
treatment, and a time-dependent increase in the frac-
tion of cells in sub-G1, indicating induction of an S-phase
checkpoint and apoptosis, respectively (Figure 1A). In
contrast, exposure to the same concentration of MNNG
had no effect on cell cycle distribution of MT1 cells
(Figure 1A). DNA fragmentation analysis showed distinct
DNA ladders in MNNG-treated TK6 cells, but not in
MNNG-treated MT1 cells (Figure 1B). These data con-
firm that TK6 cells are highly susceptible and MT1 cellare highly resistant to MNNG-induced cell cycle arrest
and apoptosis. In consistent with previous studies in
HeLa and other human cells [8,11,12,20], a 4-hour
exposure to 0.5 μM MNNG resulted in increased
(~2.5-fold) phosphorylation of an ATR/ATM substrate
with a molecular weight ~130 Kd in TK6 cells, but no
change was observed in MT1 cells (Figure 1C), suggesting
that activation of ATR/ATM signaling is dependent on a
functional MMR system.
Overview of changes in total and nuclear proteomes of
MNNG-treated TK6 and MT1 cells
To evaluate changes in protein abundance and protein
phosphorylation in MNNG-treated cells, we performed
quantitative proteomics analyses. The strategy of these
analyses is outlined in Figure 2A. The MNNG treatment
groups were cultured in SILAC (Stable Isotope Labeling
with Amino Acids in Cell Culture) light media, while
control cells (no MNNG) were grown in heavy media.
Following MNNG treatment, TK6 or MT1 cells were
either lysed with RIPA (Radio Immunoprecipitation Assay)
buffer for whole cell protein extracts or fractionated for
preparation of nuclear extracts. Western blot, using
antibodies against GAPDH and histone H3, was performed
to confirm the purity of cytoplasmic and nuclear extracts,
respectively (Figure 2B). Proteins were mixed in 1:1 (heavy:
light) ratio and digested into peptides with trypsin.
Peptides were separated into phosphopeptides and
nonphosphopeptides by IMAC (Immobilized Metal Affinity
Chromatography), then fractionated by HILIC (hydrophilic
interaction chromatography) and analyzed by nano-
RPLC-ESI-MS/MS (nano-reversed phase chromatography-
electrospray ionization-MS/MS) analysis.
The number of identified and quantified unique proteins
and phosphopeptides in the total and nuclear proteomes
of each cell line is listed in Table 1. Detailed information
regarding the identified proteins and phosphopeptides
were listed in Additional file 1: Table S1 (proteins) and
Additional file 2: Table S2 (phosphopeptides). Comparing
data from the whole cell extract to those from the nuclear
extract (Table 1), we found: 1) although the number of
identified proteins in the whole cell extract were about
30% more than in the nuclear fraction (~1,700 proteins
vs ~1,100 proteins), the number of identified phospho-
peptides in both sets (~1,500) were comparable. This
was mainly because the nuclear fractionation step made
many lower-abundant nuclear proteins detectable, dem-
onstrating that subcellular fractionation enhanced the
sensitivity in our proteomic strategy. 2) More changes
were documented in the nuclear proteome than in the
total proteome. For example, the percentage of up- or
down-regulated phosphopeptides in TK6 nuclear ex-
tract was ~18.3% (203 out of 1108 phosphopeptides
quantified), while this ratio was only ~3.7% for the whole
Figure 1 Differential cellular responses to MNNG treatment in TK6 and MT1. (A) Flow cytometric analysis of cell cycle progression. TK6 and
MT1 cells were treated with 0.5 μM MNNG for 4 h, continuously cultured in fresh media without MNNG, and harvested for flow cytometry
analysis at the indicated time points after MNNG treatment. (B) DNA fragmentation analysis. TK6 and MT1 cells were treated with 0.5 μM MNNG
for 4 h, continuously cultured in fresh media without MNNG for 72 h, harvested and extracted for genome to analyze with DNA fragmentation
experiment. (C) Detection of phosphorylation level of ATR/ATM kinase substrates at 4 h time point after 0.5 μM MNNG treatment. TK6 and MT1
cells were incubated in the presence or absence of 0.5 μM MNNG for 4 h. Whole cell lysates were analyzed by western blotting with an anti-
phospho-(Ser/Thr) ATM/ATR substrate antibody. This antibody preferentially detects endogenous levels of proteins containing the ATM/ATR
substrate motif. Equivalent gel loading was confirmed by probing with an antibody against β-Actin.
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further demonstrated the advantage and value of adding
a subcellular fractionation step.
Because significantly more up- or down- regulatory
events were documented in the nuclear extract (Table 1),
this directed our interest to the nuclear proteome, which
is considered relevant to the MNNG-induced DDR.
Therefore, we conducted detail analysis dissecting the
key differences in the nuclear proteomes in MNNG-
treated TK6 and MT1 cells.
System-level differences between the nuclear proteomes
in MNNG-treated TK6 and MT1 cells
To identify key differences between the nuclear proteomes
in MNNG-treated TK6 and MT1 cells, we performed
quantitative proteomics analyses and obtained nuclear
proteomics profiles of the two cells (see Additional file 1:
Table S1 and Additional file 2: Table S2). Systematical
comparison of the nuclear proteomes allowed us to
extract out all the up- or down-regulated proteins and
phosphoproteins from MNNG-treated TK6 and MT1
cells. We further analyzed for the extracted data for
their biological function distribution using Gene Ontology
(GO) annotation, and discovered that more than 90% ofthe up- and down-regulated proteins and phosphoproteins
could be categorized into ten GO categories. These
GO categories include: Transcription, DNA damage and
repair, DNA replication, Cell cycle, RNA processing and
splicing, Chromatin modification and nucleosome as-
sembly, Translation, Transport, Apoptosis and Protein
ubiquitination. The number of up- and down-regulated
proteins in MNNG-treated TK6 and MT1 cells that fall
into the GO categories is shown in Figure 2C and 2D
(details are listed in Additional file 3: Table S3), which
reveals the following interesting phenomena.
First, we found that there were essentially more protein
expression changes, particularly up-regulated proteins (see
red bars in Figure 2C), in MT1 cells than in TK6 cells
(194 in MT1 vs. 74 in TK6), but there were more protein
phosphorylation level changes, especially down-regulated
phosphosites (see green bars in Figure 2D) in TK6 cells than
in MT1 cells (203 in TK6 vs. 111 in MT1). Interestingly, the
changes in protein expression (Figure 2C) and protein phos-
phorylation (Figure 2D) were independent of each other.
For example, although more changes in protein expression
were observed for MT1 Transcription category (Figure 2C),
more protein phosphorylation level changes were observed
in TK6 cells (Figure 2D).
Figure 2 Experimental strategy and overview of changed nuclear proteins in TK6 and MT1. (A) Strategy for the identification and
quantification of phosphorylation stoichiometry and protein abundance in TK6 and MT1 at 4 h after 0.5 μM MNNG treatment. (B) Validation of
nuclear-extract’s purity using antibodies of GAPDH and Histone H3. (C) Functional distribution of changed proteins in TK6 and MT1. All the up- or
down-regulated proteins from MNNG-treated TK6 and MT1 nuclear proteome were analyzed through their biological process distribution based
on Gene Ontology (GO) annotation. (D) Functional distribution of changed phosphosites in TK6 and MT1. All the up- or down-regulated
phosphosites from MNNG-treated TK6 and MT1 nuclear proteome were analyzed through their biological process distribution based on Gene
Ontology (GO) annotation.
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lation proteins” in MNNG-treated MT1 cells (43 pro-
teins), while significantly fewer (9 proteins) “Translation
proteins” were up-regulated in MNNG-treated TK6
cells (Figure 2C). If this correlates with more active
translation in MNNG-treated MT1 cells than in MNNG-
treated TK6 cells, then it could explain the higher total
number of up-regulated nuclear proteins in these cells
(Table 1). We hypothesize that the preferentially up-
regulated “Translation proteins” in MNNG-treated MT1
cells may be responsible for tolerance to killing by MNNG
toxicity. Indeed, some of the up-regulated proteins thatwe identified in MT1 cells, including EF2 (Elongation
factor 2), EIF4G1 (Eukaryotic translation initiation
factor 4 gamma 1), RPL5 (60S ribosomal protein L5)
and RPL23A (60S ribosomal protein L23a) (as listed in
Additional file 1: Table S1), have been previously impli-
cated in anti-apoptosis, drug resistance and cell survival
[21-25].
Third, from the protein phosphorylation perspective,
in nearly all the GO categories outlined, we identified
more alteration in MNNG-treated TK6 cells than in
MNNG-treated MT1 cells (Figure 2D). This is especially
evident in the GO categories of “Transcription” (78 vs. 31),
Table 1 Number of peptides and proteins identified and quantified in MNNG-treated cells
Component Whole cell extract Nuclear extract
TK6 MT1 TK6 MT1
Unique phosphopeptides 1438 (FDR# = 1.9%) 1654 (FDR# = 1.6%) 1594 (FDR# = 2.7%) 1348 (FDR# = 2.3%)
Unique proteins 1792 (FDR# = 4.9%) 1765 (FDR# = 4.5%) 1238 (FDR# = 4.5%) 1102 (FDR# = 4.8%)
Phosphopeptides quantified 766 925 1108 901
Proteins quantified 1153 1198 794 724
Down-regulated phosphopeptides* 13 13 127 37
Up-regulated phosphopeptides* 15 16 76 74
Down-regulated proteins* 30 20 23 16
Up-regulated proteins* 26 29 51 178
#The FDR (false-discovery rate) of phosphopeptides was calculated by searching query sequences against a randomized SwissProt human database with
significance threshold p set to 0.05. The identified proteins were grouped by Scaffold (version 2_04_00) to eliminate redundancy and the FDR of proteins were
also calculated by Scaffold software.
*The cutoff threshold was set at 1.5-fold increase or decrease, that is, a light-to-heavy ratio (L/H) ≥ 1.5 or ≤ 0.66.
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14), and “Transport” (20 vs. 9) (Figure 2D). Because
activities in protein phosphorylation and dephosphory-
lation in general correlated with activities in cellular
signaling, we hypothesized what we observed may reflected
a functional MMR pathway in TK6 directly or indir-
ectly regulated DNA damage-related protein subnetworks
during MNNG-stimulation, suggesting that functional
MMR or functional MutSα might play an important role
in modulating a series of biological processes, and ultim-
ately leading to apoptosis in TK6 cells (Figure 1A and 1B).
Unique proteomic changes in MNNG-treated TK6 and
MT1 cells
Because we conducted the TK6 and MT1 proteomics
experiment independently (Figure 2A), some of the pro-
teins were found in one experiment, but not in another,
which is very common for mass spectrometry-based
proteomics analysis [26]. In order to directly compare
protein phosphorylation at individual protein level be-
tween TK6 and MT1, we compile a list of phosphorylation
sites with the following criteria: 1) same phosphosite was
quantified in both MNNG-treated TK6 and MT1 nuclear
fraction; 2) the phosphosite was up- or down-regulated in
at least one cell type. These phosphosites are listed in
Additional file 4: Table S4, and a corresponding heat
map is shown in Figure 3.
In the heat map (Figure 3), the color indicated the
level of phosphorylation at individual protein phosphor-
ylation sites, with the green and red colors being the
lowest and highest levels, respectively (see color diagram
at the top panel). In each of the GO categories shown in
Figure 3, protein phosphorylation sites are listed according
to their phosphorylation levels (from low to high) in TK6.
From this analysis, we deduced that: 1) the direction of
change in protein phosphorylation was rarely oppositein TK6 and MT1 cells; 2) a few phosphorylation were
up- or down-regulated in both MNNG-treated cell lines;
but 3) most phosphorylation were up- or down-regulated
in one of the cell lines and unaffected by MNNG-
treatment in the other cell line.
Among the 133 phosphorylation sites listed in Figure 3,
only one phosphorylation site, namely Ser720 of AKAP2
shown opposite change in protein phosphorylation (see
the first entry in the Unknown Miscellaneous category).
AKAP2 protein can bind to regulatory subunit (RII) of
protein kinase A [27] and may be involved in establishing
polarity in signaling systems. The biological significance
of AKAP2 protein in differential responses of TK6 and
MT1 toward MNNG-treatment remains to be investigated.
A number of protein phosphorylation sites were found
to be up-regulated in MNNG-treated TK6 nuclear prote-
ome, but not in MT1 (Figure 3). Many of these proteins,
such as RAD50, RBBP8, SMC3, TOP2A and TP53B (see
DNA damage and Repair category), were well known to
participate in DDR network. Examples demonstrating
these points are shown in Figure 4 and Additional file 5:
Figure S1. To distinguish if a change in phosphorylation
of a nuclear protein is due to increased post-translational
modifications in the nucleus or translocation of the phos-
phorylated protein from the cytoplasm, we quantified a
reference peptide that contains no phosphorylation sites
from the same protein. Thus, if a protein of interest is
elevated in nuclear extract as compared with the whole
cell extract, it implies a nuclearcytoplasmic shuttling
occurring; otherwise, the up-regulated phosphorylation
result from the post-translational modifications in the
nucleus. We found that phosphorylation of Ser1083 in
SMC3 was differentially up-regulated in the nuclear
proteome of MNNG-treated TK6 cells. This is because
the level of the phosphorylated peptide in treated nuclear
proteome is 4.5-fold higher than in untreated nuclear
Figure 3 Heat map of differential changes in protein phosphorylation between TK6 and MT1. Phosphorylation sites with the following
criteria were extracted for heat map: (1) same phosphosite was quantified in both MNNG-treated TK6 and MT1 nuclear fraction; (2) the
phosphosite was up- or down-regulated in at least one cell type. The protein accession numbers and phosphosites were labeled, and all shown
phosphoproteins were classified by their biological processes based on Gene Ontology (GO) annotation. Some phosphoproteins may exist in
several different biological processes.
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Figure 4 Examples of peptide tandem mass spectra from differentially-regulated nuclear phosphoproteins of MNNG-treated TK6 and
MT1 cells. Peptide pairs were prepared using SILAC method, with the "light" labeling as MNNG treatment group. (A) Peptide pairs
(GSGpSQSSVPSVDQFTGVGIR, ALDQFVNFSEQK, DLQDELAGNSEQR) from SMC3 protein, (B) Peptide pairs (ILDPNTGEPAPVLSpSPPPADVSTFLAFPSPEK,
MAVQDAVDALMQK) from RAGP1 protein.
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phorylation level of Ser1083 of SMC3 kept the same in
treated and untreated MT1 cells (Figure 4A, upper right).
Since the abundance of a non-phosphopeptide of SMC3
was unchanged (lower spectrum), the observed up-
regulation of SMC3 phosphorylation in MNNG-treated
TK6 proteome is a result of post-translational modifica-
tions by protein kinase(s) activated during the treatment.
A similar result was also observed for Ser831 in TP53B
and Ser1233 in SRRM2 (Additional file 5: Figure S1). All
these three proteins are predicted substrates of ATM/ATR
kinases (see below), whose role in DDR is well-established
[28,29].
It is interesting to note that while we detected phos-
phorylation up-regulation of some important DDR factors
in TK6 cells, we also identified more phosphorylation
up-regulation of components involved in apoptosis in
MNNG-tolerant MT1 cells than in MNNG-sensitive TK6
cells (see Figure 3, the GO category of “Apoptosis”). These
proteins include anti-apoptotic ERCC5 (Ser384) and
pro-apoptotic VDAC1 (Ser104), LAP4 (Ser1448), SH3K1
(Ser230), and SHIP1 (Ser971). This phenomenon appears
to suggest that MNNG-induced phosphorylations have
greatly altered the biological functions of these apoptosis-
related proteins, i.e., inhibiting the pro-apoptotic activ-
ities of VDAC1, LAP4, SH3K1 and SHIP1, but enhancing
the anti-apoptotic activity of ERCC5. However, further
investigations are required to verify these possibilities.Activation of nucleocytoplasmic shuttling in TK6 cells
upon exposure to MNNG
The comparative mass spectrometry analysis of phospho-
protein between nuclear extract and whole cell extract
allowed us to identify an important phenomenon asso-
ciated with MNNG treated TK6 cells, i.e., activation of
nucleocytoplasmic transport. As shown in Figure 4B,
phosphorylation of Ser428 in Ran GTPase-activating pro-
tein 1 (RanGAP1), a critical regulator of the small GTPase
Ran (RAN)-dependent nucleoplasmic transport [30-32],
was up-regulated 1.8 fold in the nuclear proteome of
MNNG-treated TK6 cells, but the up-regulation was not
detected in MNNG-treated MT1 cells (upper spectra).
Because RanGAP1 is located primarily within the cyto-
plasm [33] and because Ser428 phosphorylation was
observed previously in an MNNG-independent manner
[34], we suspected that the up-regulated RanGAP1 level
in the TK6 nucleus is likely due to transport of the pro-
tein from the cytoplasm. Indeed, we observed 1.8-fold
up-regulation of a reference peptide of RanGAP1 in the
TK6 nuclear extract (Figure 4B, lower spectrum), but
not in the TK6 whole cell extract (data not shown).
These results strongly suggest that the up-regulated nu-
clear RanGAP1 in MNNG-treated TK6 cells is a result
of translocation of the protein from cytoplasm. Simi-
larly, we detected nucleocytoplasmic shuttling of RAN,
an essential player of the RAN-dependent nucleocytopasmic
transport [30,31]. Since this phenomenon was only observed
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RanGAP1-dependent nucleocytoplasmic shuttling could
be part of the MMR-mediated signaling network. Fur-
ther studies are required to explore this possibility.
A DDR protein interaction network in TK6 cells
When comparing MNNG-treated nuclear phosphoproteome
in TK6 and MT1 cells, we noticed significantly more pro-
tein phosphorylation level changes in TK6 cells than in
MT1 cells (203 in TK6 vs. 111 in MT1). Are these reg-
ulations on protein phosphorylation related to a DDR
protein interaction network? To address this question,
all phospho- and nonphospho-proteins identified in TK6Figure 5 Protein networks analysis in TK6 nuclear extract. (A) Protein
and abundance data in TK6 nuclear were analyzed with the STRING databa
representative subgroups (“DNA damage and repair” and “Apoptosis”) If bo
information in phosphorylation was shown. (B) Kinase-substrate interaction
predict potential kinases for quantified phosphosites in “DNA damage and
phosphosites represented their alteration after MNNG treatment.(as listed in Additional file 1: Table S1 and Additional
file 2: Table S2) were queried for protein interactions
using the program STRING (version 8.2) (http://string-
db.org/) [35]. STRING integrates known and predicted
interactions from multiple sources to generate a putative
interaction network map for a given data set. A network
of 1285 proteins (nodes) and 8427 connections (edges)
were obtained (Additional file 6: Figure S2).
To enhance this data analysis, five subnetworks, com-
prised of proteins with shared GO terms/function, were
examined in greater detail: the DNA damage and repair
subnetwork included 90 proteins and 536 connections
(Figure 5A, left panel), the Apoptosis subnetwork includedinteraction Networks in TK6 nuclear extract. Protein phosphorylation
se. A GO biological process analysis was performed to create two
th protein expression and phosphorylation data were available, only
networks in TK6 nuclear extract. NetworKIN algorithm was used to
repair” and “Apoptosis” biological processes. The color of the
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the RNA processing and splicing subnetwork included
73 proteins and 435 connections (Additional file 6:
Figure S2), the Cell cycle subnetwork included 89 pro-
teins and 331 connections (Additional file 6: Figure S2),
and 59 proteins and 102 connections were present in the
Transcription subnetwork (Additional file 6: Figure S2).
These five subnetworks included most of the TK6
MNNG-sensitive proteome subfraction, and included a
highly interconnected group of TK6 proteins. Further-
more, for the proteins in these five subnetworks, MNNG-
induced changes in phosphorylation status were more
common than MNNG-induced changes in protein abun-
dance. Thus, protein phosphorylation clearly mediates
critical regulatory events during the early stages of
MNNG-induced DDR in MMR-proficient TK6 cells.
ATM (ataxia telangiectasia mutated) and ATR (ATM
and Rad3-related), members of the phosphoinositide
3-kinase related kinase (PIKK) family, are well-recognized
master regulators of DDR. Together with other regulator
and mediator proteins, ATM and ATR stimulate phos-
phorylation of Chk1 and Chk2, which in turn activate
signaling cascades via a large number of downstream
effector proteins, such as MCMs, RFC, TopBP1, Rad51
and FANCD2 [36]. Our proteomics data also showed
increased expression or phosphorylation of BRCA1, NBN,
RAD50, TP53BP1, SMC3, TOP2A, RBBP8, LIG3 and
TERF2IP, all members of the DNA damage and repair
subnetwork (Figure 5A). Previous studies suggested that
NBN plays a role in the cellular response to MNNG
[37], and that phosphorylation of SMC3, RAD50 and
TP53BP1 increased in IR-treated cells [38]. Together,
these data help validate our proteomics approach and
analysis. However, a number of proteins with known roles
in DDR, such as Chk1, Chk2, p53, RAD17, XRCC2,
ERCC1 and MDC1, were not identified as DDR network
components in this study. This may indicate that these
low abundance proteins fell below the detection limit
associated with the instrumentation and analytical pro-
cedures used in this study. On the other hand, we iden-
tified a number of novel putative DDR proteins events,
which have not previously been linked to DDR (see below).Prediction of DDR protein kinase networks in
MNNG-treated TK6 cells
Our quantitative phosphoproteomic analysis provided
information regarding protein phosphorylation regulation
upon MNNG-treatment. In order to use our data to
explore protein kinases that may participate in DDR
network, we used the NetworKIN algorithm to predict
which kinases were responsible for MNNG-induced
phosphorylation events within the DNA damage and
repair, Apoptosis, Cell cycle and RNA processing andsplicing subnetworks in TK6 cells (Figure 5B and
Additional file 7: Figure S3).
We identified ATM or ATR as projected kinases for
several proteins with up-regulation in phosphorylation.
Because these protein substrates, NBN (Ser343), RAD50
(Ser635), TP53B (Ser580, Ser831) and SMC3 (Ser1083),
are known players, and ATM/ATR are known master
regulators in DDR, this finding further validated our
phosphoproteomics approach in study cellular responses
to MNNG treatment.
In addition, our analysis also project some other kinases,
such as CDK2 (a cyclin-dependent protein kinase), Casein
kinase II, and MAP kinase may be responsible for the
phosphorylation of many protein substrates participating
in “DNA damage and repair”, “Apoptosis”, “Cell cycle”
and “RNA processing and splicing” in MNNG-treated
TK6 cells (Figure 5B and Additional file 7: Figure S3),
indicating that these kinases may also play important
regulatory roles in MNNG-induced DDR.
Some proteins may be targeted by more than one
protein kinase in MNNG-treated TK6 cells, suggesting
that DDR involves coordinated regulatory activities and
cross-talk between multiple kinases in TK6 cells. For
example, S635 in RAD50, up-regulated 6.3-fold, is an
ATM/ATR target, while T690 in RAD50, up-regulated
5.5-fold, is a target of Casein kinase II (Figure 5B).
Although unbiased phosphoproteomics analysis and
system biology-based network investigation can provide
insight into cellular signaling, in many cases, traditional
molecular biology-based study, combined with functional
assays are needed to identify and screen for the biological
significance of predicted phosphorylation. Many protein
phosphorylation sites we discovered are consistent with
previous knowledge accumulated over the years using
molecular biology method, giving credibility to our system
biology level approach. For example, Ser343 phosphoryl-
ation in NBN (a ATM/ATR kinase substrate, Figure 5B)
was identified previously as closely related with NBN-
regulated apoptosis, and a mutation in the ATM/ATR
phosphorylation site (Ser343A) leads to a severe inhibition
of apoptosis [39]. The CDK2 kinase substrate RBBP8
(Ser327) (Figure 5B), a putative tumor suppressor, was
recently shown to be involved in regulating the G2/M
checkpoint through BRCA1-dependent ubiquitination in
response to Ser327 phosphorylation [40] and to counter-
act Rb-mediated G1 restraint [41].
The large amount of information about regulations on
protein phosphorylation generated from our study may
provide new hints into mechanism of protein interaction.
For example, Thr690 of RAD was identified as being
up-regulated in MNNG-treated TK6 nuclear, with Casein
Kinase II as its potential kinase (Figure 5B). RAD50 has
a Cys-X-X-Cys motif of the zinc-hook structure located
in the middle of the coiled-coil domain, which functions
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The RAD50 hook is very important in forming a complex
of MRE11/RAD50/NBN (MRN complex), which acts a
double-strand break sensor for ATM and recruits ATM
to broken DNA molecules and activates ATM to initiate
phosphorylation-network-based apoptosis [42,43]. Inter-
estingly, the Thr690 residue is located in the zinc-hook
of RAD50. Therefore, it is speculated that the up-
regulated phosphorylation on Thr690 site affects RAD50
dimerization, further influences the formation of MRN
complex, leading to a series of downstream apoptosis-
related protein interactions.
Conclusions
TK6 and MT1 cells are two closely-related cell lines,
mainly different in the existence of MSH6 [17,18]. How-
ever, MT1 cells are >500-fold more resistant to MNNG-
induced apoptosis than TK6 cells [16]. Consistent with
these genetic and phenotypic differences, the unbiased
proteomics analysis in this study reveals significant dif-
ferences in the nuclear proteome of TK6 and MT1 cells
(Figures 2 and 3) during their early stage (4-hour) re-
sponses to MNNG treatment. Because MNNG not only
can react with nucleic acid, it also can react with pro-
teins [44], the differential responses in MNNG-treated
TK6 and MT1 cells should be considered as the collect-
ive response of MNNG-nucleic acid and MNNG-protein
interactions. A summary of main differential effects of
MNNG on TK6 and MT1 proteome was illustrated in
Figure 6. The key findings of this study include: 1)
MNNG-induced phosphophorylation events are more
frequent in TK6 than in MT1 cells (Table 1), suggestingFigure 6 Hypothetic mechanism of differential responses to MNNG tr
proportion of down- or up-regulated changes. (pp) represents protein-pho
protein expression (pe) level change upon MNNG treatment.that MSH6 plays an important role in initiating MNNG-
induced DDR and apoptosis; 2) MNNG-induced changes
(mostly up-regulation) of protein expression/abundance
were more frequent in MT1 than in TK6 cells, especially
for Translation proteins (Figure 2C), allowing MT1 to
establish an anti-apoptotic response in the absence of
MMR function; 3) ATM/ATR, CDK2, Casein kinase II
and MAP kinases are predicted to play a role in DDR-
associated phosphorylation events in MNNG-treated TK6
cells (Figure 5B and Additional file 7: Figure S3); 4) MNNG-
treated TK6 cells may undergo RAN/RanGAP1-dependent
nucleocytoplasmic transport of proteins, allowing shuttling
of mRNAs and apoptotic stimuli between the nucleus and
the cytoplasm, leading to initiation of apoptosis. However,
it should be emphasized that the conclusions and the
model are based on a single time-point “snap shot” of the
TK6 and MT1 nuclear and total proteomes, and their
confirmation requires additional thorough investigations.
Methods
Cell culture, flow cytometry and DNA fragmentation analysis
TK6 and MT1 cell lines were cultured in RPMI 1640
medium (GIBCO) supplemented with 10% heat-inactivated
undialyzed fetal bovine serum (Hyclone), 100 U of penicil-
lin and 100 μg/mL of streptomycin (Invitrogen) in a hu-
midified incubator with 5% CO2 at 37°C.
For flow cytometry analysis, cells were treated or mock-
treated with 0.5 μM MNNG and incubated for the indi-
cated time periods. A total of 1.0 × 106 cells were washed
with ice-cold PBS and fixed in ice-cold 70% ethanol over-
night. The cells were then treated with 100 μg/mL RNase
A for 1 h at 37°C and stained with 50 μg/mL propidiumeatment in TK6 and MT1. The green or red bar represents the
sphorylation (pp) level change upon MNNG treatment. (pe) represents
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was performed using a BECKMAN COULTER EPICS XL
flow cytometer and the EXPO32ADC software.
For DNA fragmentation analysis, cells were treated or
mock-treated with 0.5 μM MNNG and incubated for the
indicated time periods. A total of 5 × 105 cells were washed
with ice-cold PBS, centrifuged for 5 min at 400 × g, and
resuspended in 40 μL cell lysis buffer (20 mM EDTA,
100 mM Tris, pH8.0 and 0.8% (w/v) SDS). RNase A (2 μL
of 1 mg/mL, Fermentas) was added and incubated for
120 min at 37°C, then 10 μL Proteinase K (20 mg/mL,
TaKaRa) was added and incubated for at least 90 min at
50°C. Sample was mixed with 10 × DNA loading buffer
(TaKaRa), and loaded onto a 2% agarose gel. Electro-
phoresis was conducted at 2–4 V/cm for approximately
6 h. The DNA was stained with 1 μg/mL ethidium brom-
ide (Sigma) in TAE buffer.
SILAC labeling, MNNG treatment and western blot
Cells were washed twice with RPMI 1640 medium without
Arg and Lys (Thermo Scientific Pierce) and reconstituted
in RPMI 1640 medium containing either 12C6,
14 N4 Arg,
12C6,




15 N2 Lys (Sigma) and normal L-proline. The
media also contain 10% heat inactivated dialyzed fetal
bovine serum (Thermo Scientific Pierce), 100 U of peni-
cillin and 100 μg/mL of streptomycin. Cells were cultured
in a humidified incubator (5% CO2) at 37°C for ~8 cell
doublings. The concentration of Arg and Lys used in
SILAC labeling of TK6 and MT1 cell lines was 0.398 mM
and 0.798 mM respectively. Adding additional L-proline
(200 mg/liter) should reduce arginine to proline conver-
sion [45].
Cells were treated with or without 0.5 μM MNNG for
4 hours, and harvested by centrifugation at 400 g. Cell
pellets were washed three times with cold PBS, and lysed
for 30 min at 4°C in RIPA buffer (25 mM Tris–HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1%
SDS) containing phosphatase inhibitor cocktail (PhosSTOP,
Roche Applied Science) and protease inhibitor cocktail
(COMPLETE, Roche Applied Science). After centrifuga-
tion for 15 minutes at 16000 g, the supernatant was
collected and saved as whole cell protein extract.
For the immunoblotting, a small aliquot of proteins
from MNNG-treated TK6 and MT1 cells were separated
by SDS-PAGE, transferred electrophoretically onto a PVDF
membrane (Amersham) and blocked for 1 h with TBST
containing 5% nonfat milk. The PVDF membranes were
incubated with the primary antibody overnight at 4°C,
washed three times with TBST, incubated with a horse-
radish peroxidase-conjugated secondary antibody for 1 h
at room temperature, and then developed with a chemilu-
minescent reagent (SuperSignal® West Pico Chemilumin-
escent Substrate, PIERCE). Primary antibodies wererabbit anti-human Phospho-(Ser/Thr) ATM/ATR sub-
strate antibody (Cell Signaling Technology) or rabbit
anti-human β-Actin antibody (Cell Signaling Technology).
Nuclear protein extraction
All nuclear-protein-extraction steps were conducted on
ice or at 4°C. Cell pellets were re-suspended in 10 vol-
umes of ice-cold buffer A (10 mM Tris–HCl (pH7.4),
5 mM MgCl2, 10 mM NaCl, 1 mM DTT, plus proteinase
inhibitor cocktail (Roche), phosphatase inhibitor cocktail
(Roche)) and incubated on ice for 20 min. Then ice-cold
buffer B (10 mM Tris–HCl (pH7.4), 5 mM MgCl2,
10 mM NaCl, 1 mM DTT, proteinase inhibitor cocktail,
phosphatase inhibitor cocktail, 10% NP-40) was added,
adjusting the final concentration of NP-40 to 0.5%. After
vigorous vortexing on the highest setting for 5 s, the
tube was incubated on ice for 1 min, then vortexed for
another 5 s. The extract was centrifuged for 5 min at
500 × g, and the supernatant fraction (cytoplasmic ex-
tract) removed and saved. The pellet was washed with
5 volumes of ice-cold buffer A to minimize cytoplamic
protein contamination, then re-centrifuged for 5 minutes
at 500 × g to obtain the nuclei as pellet. The nuclear pellet
was resuspended in 10 volumes of freshly prepared buffer
C (20 mM HEPES-KOH (pH7.9), 1.5 mM MgCl2, 0.5 M
NaCl, 1 mM DTT, 0.2 mM EDTA, 20% (V/V) glycerol,
proteinase inhibitor cocktail, phosphatase inhibitor cock-
tail). The nuclear proteins were solubilized by vortexing
3 times for 15 s at 10 min intervals, after which the
extract was centrifuged at 16000 × g for 30 min. The
supernatant (nuclear proteins extract) was immediately
transferred to a pre-chilled tube. The purity of the
nuclear and cytoplasmic protein extracts was evaluated
by Western Blot for Histone H3 (as a nuclear protein
marker) and GAPDH (as a cytoplasmic protein marker)
by using rabbit anti-human GAPDH Antibody (Cell
Signaling Technology) and rabbit anti-human Histone
H3 Antibody (Cell Signaling Technology) as primary
antibodies.
Protein digestion and phosphopeptide enrichment
Proteins were precipitated with 3 volumes 50% acetone/
50% ethanol/0.1% acetic acid on ice for 1 h. After centri-
fugation at 10000 × g for 15 min, the protein pellet was
resuspended in 8 M urea/0.2 M Tris, pH 8/4 mM CaCl2.
Proteins were reduced with 10 mM DTT for 1 h at 56°C,
alkylated with 40 mM iodoacetamide for 30 min at room
temperature in the dark. After diluting sample 7-fold,
trypsin (Worthington) was added in a 1:50 (trypsin/
protein) w/w ratio, and incubated overnight at 37°C.
Tryptic peptides from whole cell or nuclear protein
extracts were loaded onto a 2 g Sep-Pak C18 column
(Waters), washed twice with 10 mL 1% acetic acid, eluted
with 7 mL 80% acetonitrile containing 0.1% acetic acid,
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1% acetic acid and loaded onto a mini column of 40 μL
IMAC resin (prepared as previously described [46,47]).
The IMAC minicolumn was washed twice with 40 μL
wash buffer containing 25% acetonitrile, 100 mM NaCl
and 0.1% acetic acid, then washed once each with 40 μL
1% acetic acid and 20 μL deionized water, eluted with
120 μL 6% NH4OH, and dried under vacuum. The
IMAC column flow-through, which contains mainly
non-phosphopeptides, was also collected.HILIC workflow
Enriched phosphopeptides and non-phosphopeptides were
fractionated separately using a TSKgel Amide-80 column
(2.0 mm× 150 mm, 5 μm particle size, 200 Å pore size)
(TOSOH Bioscience) on a Agilent 1200 system (Agilent
Technologies). A 60 min elution gradient was used for
phosphopeptide separation with 90% ACN, 0.005% TFA as
Buffer A and 0.005% TFA as Buffer B. The gradient elution
profile composed of 0%-12% B for 5 min, 12-30% B for
25 min, 30-90% B for 5 min, then maintained at 90% B for
5 min, followed by 10-100% A for 5 min, ending at 100% A
for 15 min. The flow rate was 0.15 mL/min. UV absorbance
was monitored at 215 nm. A total of 26 0.3 mL fractions
were collected. Fractions were dried via vacuum. Non-
phosphopeptides were fractionated in essentially the same
manner, except that the gradient elution profile was
0%-5% B for 5 min and then 5-30% B for 25 min.RPLC-ESI-MS/MS
A QSTAR ELITE mass spectrometer (Applied Biosystems)
was coupled with an online Eksigent nano MDLC systems
utilizing a nanospray ionization source. Peptides were
first enriched with a CapTrap column (0.5 mm × 2 mm,
MICHROM Bioresources, Inc.) followed by elution into
an integrated nanoscale analytical column (MAGIC C18AQ,
100 μm×150 mm, 3 μm particle size, 200 Å pore size,
MICHROM Bioresources, Inc.). Mobile phase A (2% ACN,
0.1% formic acid) and mobile phase B (98% ACN, 0.1%
formic acid) were used to establish a 130 min gradient
comprised of 5 min 5% B, then 25 min 5-15% B, followed
by 55 min 15-40% B, then 15 min 40-80% B, maintained at
80% B for 10 min, then 5 min 80-5% B, finally maintained
at 5% B for 15 min. The flow rate was ~300 nL/min. We
conducted MS from 400 to 1800 amu, with 1 s time spans.
For MS/MS analysis, each scan cycle consisted of one full-
scan mass spectrum (with m/z ranging from 400 to 1800
and charge states from 2 to 5) followed by five MS/MS
events. Threshold count was set to 30, and the exclusion
window was 90 s. Mass tolerance was 50 mDa. Automatic
Collision Energy and Automatic MS/MS Accumulation
were selected.Database searching
The raw data collected by QSTAR ELITE were presented
by Mascot Daemon (version 2.2.2) (Matrix Science, London,
UK) to an in-house MASCOT server (version 2.2) (Matrix
Science, London, UK) and Distiller (version 2.2.1.2) (Matrix
Science, London, UK). Briefly, peak lists were generated
by Distiller and searched against a target/decoy SwissProt
human protein database (version 57.7; 20405 sequences)
by MASCOT server. Spectra match criteria were as fol-
lows: Fixed modification was carbamidomethyl at Cys
residue, whereas variable modifications were oxidation at
Met residue, and phosphorylation at Ser, Thr or Tyr resi-
dues, additionally Arg10 and Lys8 were set as exclusive
modifications, which is a useful setting in MASCOT that
can be thought of as a choice of fixed modifications to
speed up the search and reduce the significance thresh-
olds, and taxonomy was set to “human”. Peptide and MS/
MS tolerances were 50 ppm and 0.2 Da, respectively. The
peptide charges were 2+, 3+, 4+, or 5+, allowing up to two
missed cleavages. The significance threshold was p < 0.05.
Quantitation analysis
The rov data obtained from database search were opened
by Mascot Distiller for quantitation. For the quantitation
analysis, we set Fraction, Correlation and Std. Err at 0.5,
0.9 and 0.2, respectively. The peptide ratios were calcu-
lated as weighted average ratios (ion intensity versus ratio)
if several spectra for the same peptide were available. Pro-
tein ratios were also calculated as the weighted average
ratios (ion intensity versus ratio). In a few situations, out-
liers were removed for more accurate quantitation. The
median of all quantitation data from non-phosphopeptides
was used to normalize the peptide ratios.
STRING network analysis
Identified proteins (accession number) were presented
to STRING 8.2 database (http://string-db.org/) [35] to
construct networks. Then networks were extracted and
loaded into Cytoscape (version 2.6.3) (http://www.cytoscape.
org/) [48] for compilation and visualization. Protein
networks identified by STRING consisted of protein IDs
(nodes) and protein-protein interactions (edges). Only
interactions with a score of 0.400, which represents the
default medium confidence level in STRING, were kept.
NetworKIN analysis
In order to predict potential kinases for quantified phos-
phosites, we used the NetworKIN algorithm which aug-
ments motif-based predictions with the network context
of kinases and phosphoproteins and can assign a specific
kinase to an identified in vivo phosphosite with a 2.5-fold
higher accuracy than previous methods such as Scansite
and NetphosK [49]. After loading the data to NetworKIN
2.0 (http://networkin.info/version_2_0/newPrediction.php),
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Cytoscape (version 2.6.3). Manual network layout was
then performed to display interactions between kinases
and phosphosites, using color-coding to indicate fold
increase or decrease.Additional files
Additional file 1: Table S1. Detail information in proteins identified
and quantified in whole cell and nuclear extracts from MNNG-treated TK6
and MT1 cells. ‘L’ (light) represents MNNG-treatment group, and ‘H’
(heavy) represents mock-treatment group.
Additional file 2: Table S2. Detail information in phosphopeptides
identified and quantified in whole cell and nuclear extracts from
MNNG-treated TK6 and MT1 cells. ‘L’ (light) represents MNNG-treatment
group, and ‘H’ (heavy) represents mock-treatment group.
Additional file 3: Table S3. Detail information in changes respectively
in protein expression and protein phosphorylation from MNNG-treated
TK6 and MT1 cells. ‘L’ (light) represents MNNG-treatment group, and ‘H’
(heavy) represents mock-treatment group.
Additional file 4: Table S4. Detail information in phosphosites quantified
in both TK6 and MT1 nuclear extract. ‘L’ (light) represents MNNG-treatment
group, and ‘H’ (heavy) represents mock-treatment group.
Additional file 5: Figure S1. Examples of peptide tandem mass spectra
from differentially-regulated nuclear phosphoproteins from MNNG-treated
TK6 and MT1 cells. Displayed were mass spectra of peptide pairs prepared
using SILAC method, with the “light” labeling as MNNG-treatment group.
Additional file 6: Figure S2. Protein Networks in TK6 nuclear extract.
Protein phosphorylation and abundance data in TK6 nuclear extract were
analyzed with the STRING database. A GO biological process analysis was
performed to extract several representative subgroups (including “RNA
processing and splicing”, “Cell cycle” and “Transcription”), as well as a
complex network composed of 1285 proteins (nodes) and 8427
connections (edges). If both protein expression and phosphorylation data
were available, only information in phosphorylation was shown.
Additional file 7: Figure S3. Kinase-substrate interaction networks in
TK6 nuclear extract. NetworKIN algorithm was used to predict potential
kinases for quantified phosphosites in “Cell cycle” and “RNA processing
and splicing” biological processes. The color of the phosphosites
represented their alteration after MNNG treatment.Competing interests
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